Literature DB >> 23791309

Identification of mutation in NPC2 by exome sequencing results in diagnosis of Niemann-Pick disease type C.

Afagh Alavi1, Shahriar Nafissi, Hosein Shamshiri, Maryam Malakooti Nejad, Elahe Elahi.   

Abstract

We report identification of a homozygous mutation in NPC2 in two Iranian siblings with a neurologic dysfunction whose disease had not been diagnosed prior to our genetic analysis. The mutation was identified by exome sequencing. The finding resulted in diagnosis of Niemann-Pick disease type C (NPC) in the siblings, and initiation of treatment with Miglustat. The clinical features of the patients are presented. It has been suggested that NPC is under diagnosed, particularly when presentations are not very severe, as was the situation in the cases studied here. NPC is a fatal autosomal recessive disorder clinically characterized by hepatosplenomegaly and progressive neurological deterioration. At the cellular level, it causes aberrant cholesterol trafficking and accumulation of unesterified cholesterol in lysosomes. Mutations in NPC1 and NPC2 are cause of disease in respectively, 95% and 5% of NPC patients. The p.Pro120Ser causing mutation in NPC2 observed in the Iranian patients was earlier observed in the only other NPC2 patient reported from the Middle East. The study demonstrates that in addition to greatly facilitating gene discovery, exome sequencing has notable potentials for diagnosis, particularly for diagnosis of atypical cases.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  ALS; C9orf72; DTR; Exome sequencing; HGMD; LDL; MRI; NPC; NPC1; NPC1 gene; NPC2; NPC2 gene; Niemann–Pick C; Niemann–Pick type C; PCR-RFLP; SMPD1; SOD1; Superoxide desmutase 1 gene; The Human Gene Mutation Database; amyotrophic lateral sclerosis; chromosome 9 open reading frame 72 gene; deep tendon reflex; low density lipoprotein; magnetic resonance imaging; p.Pro120Ser; polymerase chain reaction-restriction fragment length polymorphism; sphingomyelin phosphodiesterase 1 gene

Mesh:

Substances:

Year:  2013        PMID: 23791309     DOI: 10.1016/j.ymgme.2013.05.019

Source DB:  PubMed          Journal:  Mol Genet Metab        ISSN: 1096-7192            Impact factor:   4.797


  4 in total

Review 1.  Lysosomal diseases: diagnostic update.

Authors:  Bryan Winchester
Journal:  J Inherit Metab Dis       Date:  2014-04-08       Impact factor: 4.982

2.  Niemann-Pick Type C-2 Disease: Identification by Analysis of Plasma Cholestane-3β,5α,6β-Triol and Further Insight into the Clinical Phenotype.

Authors:  J Reunert; A S Lotz-Havla; G Polo; F Kannenberg; M Fobker; M Griese; E Mengel; A C Muntau; P Schnabel; O Sommerburg; I Borggraefe; A Dardis; A P Burlina; M A Mall; G Ciana; B Bembi; A B Burlina; T Marquardt
Journal:  JIMD Rep       Date:  2015-03-13

Review 3.  Niemann-Pick disease treatment: a systematic review of clinical trials.

Authors:  Alejandro Santos-Lozano; Diana Villamandos García; Fabian Sanchis-Gomar; Carmen Fiuza-Luces; Helios Pareja-Galeano; Nuria Garatachea; Gisela Nogales Gadea; Alejandro Lucia
Journal:  Ann Transl Med       Date:  2015-12

Review 4.  Exacerbating and reversing lysosomal storage diseases: from yeast to humans.

Authors:  Tamayanthi Rajakumar; Andrew B Munkacsi; Stephen L Sturley
Journal:  Microb Cell       Date:  2017-08-25
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.